Nona Biosciences and Dragonfly Therapeutics have signed a partnership agreement to discover and develop heavy chain only antibody (HCAb)-based drugs.
Under the deal, the completely human HCAb transgenic mice platform of Nona will be used for developing completely human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.
Go deeper with GlobalData
As per the partnership, Nona will offer Dragonfly access to its HCAb technologies and antibody generation services for the targets chosen by the latter.
Both companies have not divulged the financial details of the collaboration.
Harbour BioMed founder, chairman and CEO Dr Jingsong Wang said: “The Dragonfly Therapeutics’ collaboration recognises the potential of both our proprietary platform and antibody discovery capabilities.
See Also:
“We believe that our HCAb technology together with our accumulated extensive experience in innovative biologics drug discovery will help our partners generate differentiated therapeutic molecules benefiting the patient worldwide.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNew ‘heavy chain only’ antibodies, nearly half the size of a standard IgG, are created using HCAb’s technology.
These antibodies possess IgG-like PK characteristics and Fc-domain works without requiring further engineering or humanisation.
The latest agreement comes after Nona entered a licence and partnership agreement with Moderna for nucleic acid-based immunotherapies for chosen oncology targets.
Under the partnership deal, Nona was entitled to receive an upfront payment as well as payments on meeting specific regulatory, development and sales-based milestones and tiered royalty payments.
In April this year, Dragonfly and AbbVie expanded their research collaboration to discover and develop the new immunotherapies of the former for new targets in fibrotic and autoimmune diseases.
